Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PRCT Stock Chart & Stats
$27.40
-$0.85(-0.97%)
At close: 4:00 PM EST
$27.40
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$27.23 - $73.35
Previous CloseN/A
Volume113.34K
Average Volume (3M)975.61K
Market Cap
$1.53B
Enterprise Value$1.39B
Total Cash (Recent Filing)$294.28M
Total Debt (Recent Filing)$78.93M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Feb 24, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding55,878,590
10 Day Avg. Volume1,124,623
30 Day Avg. Volume975,607
Financial Highlights & Ratios
PEG Ratio2.10
Price to Book (P/B)10.43
Price to Sales (P/S)18.70
P/FCF Ratio-40.50
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue4.64
Enterprise Value/Gross Profit7.18
Enterprise Value/Ebitda-18.59
Forecast
1Y Price Target
$49.60Price Target Upside81.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Execution And UtilizationAnalyst highlights new commercial initiatives and CEO-led onboarding strategies that are improving procedure utilization across the installed base and supporting revenue expansion.
Growth Outlook And ValuationAnalyst notes projected top-tier revenue growth for 2026 versus peers combined with a deep valuation discount, creating potential for a re-rating if execution continues.
Path To ProfitabilityAnalyst cites an achievable path to adjusted EBITDA and free cash flow breakeven by 2027 driven by mix-driven margin expansion and operational efficiency gains.
Bears Say
Execution Risk On FY26 TargetsAnalyst warns that improved operational execution is required to build confidence in FY26 targets, exposing the stock to downside if operational improvements do not materialize.
Inventory Destocking And Working CapitalManagement commentary about inventory de-stocking and field stocking rate concerns could keep investor anxiety elevated around utilization and inventory metrics.
Sales-cycle And Commercial UncertaintyOngoing sales force changes and reports of longer HYDROS sales cycles may sustain soft sentiment amid fears of lumpy capital placements.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $27.23 and its highest was $73.35 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.53B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Feb 24, 2026 which is in 17 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Nov 04, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.032.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.32.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 55,878,590 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went down -9.737%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.60 (81.02% Upside)
$49.60 (81.02% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.87%
12-Months-Change
Fundamentals
Return on Equity
-27.22%
Trailing 12-Months
Asset Growth
36.72%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Company Deck
PRCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects strong revenue growth and significant increases in both U.S. and international sales, alongside positive gross margin expansion. However, persistent net losses, challenges in utilization growth, and anticipated procedural headwinds present concerns. The company remains optimistic about its strategic initiatives and long-term growth potential.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$49.60
▲(81.02% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.04% Insiders
37.54% Mutual Funds
0.10% Other Institutional Investors
43.83% Public Companies and Individual Investors